z-logo
open-access-imgOpen Access
The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Sexually Active Women Aged 16–26 Years
Author(s) -
Cosette M. Wheeler,
Susanne K. Kjær,
Kristján Sigurðsson,
OleErik Iversen,
Mauricio Hernández-Ávila,
Gonzalo Pérez,
Darron R. Brown,
Laura A. Koutsky,
Eng Hseon Tay,
Patricia García,
Kevin A. Ault,
Suzanne M. Garland,
Sepp Leodolter,
SvenEric Olsson,
Grace Tang,
Daron G. Ferris,
Jorma Paavonen,
Marc Steben,
F. Xavier Bosch,
Joakim Dillner,
Elmar A. Joura,
Robert J. Kurman,
Sławomir Majewski,
Nubia Muñóz,
Evan R. Myers,
Luisa L. Villa,
Frank J. Taddeo,
Christine C. Roberts,
Amha Tadesse,
Janine T. Bryan,
Lisa Lupinacci,
Katherine Giacoletti,
Margaret K. James,
Scott Vuocolo,
Teresa M. Hesley,
Eliav Barr
Publication year - 2009
Publication title -
the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1086/597309
Subject(s) - medicine , cervical intraepithelial neoplasia , cervical cancer , confidence interval , hpv infection , population , vaccination , papillomaviridae , gynecology , immunology , cancer , environmental health
We evaluated the impact of a quadrivalent human papillomavirus (HPV) vaccine on infection and cervical disease related to 10 nonvaccine HPV types (31, 33, 35, 39, 45, 51, 52, 56, 58, and 59) associated with >20% of cervical cancers. The population evaluated included HPV-naive women and women with preexisting HPV infection and/or HPV-related disease at enrollment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom